20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
22:42 , Apr 1, 2019 |  BC Extra  |  Company News

Management tracks: AACR, Acadia, Aerie

The American Association for Cancer Research inaugurated Elaine Mardis as president for 2019-20. She is the co-executive director of the Institute for Genomics Medicine at Nationwide Children’s Hospital and a professor of pediatrics at Ohio...
22:38 , Mar 19, 2019 |  BC Extra  |  Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

The Medicines Co. (NASDAQ:MDCO) terminated the employment of Christopher Cox, EVP and chief corporate development officer, effective March 15. Details were not disclosed. Mallinckrodt plc (NYSE:MNK) hired Bryan Reasons as CFO. He will succeed interim...
00:17 , Feb 16, 2019 |  BioCentury  |  Finance

Andera looks early for cancer immunotherapy

Andera Partners changed gears with an early investment in preclinical company Grey Wolf Therapeutics to diversify its cancer immunotherapy portfolio. Along with Canaan Partners, Andera backed a £10 million ($12.9 million) series A for Grey...
21:35 , Jan 11, 2019 |  BioCentury  |  Emerging Company Profile

Artios: Probing DNA Damage

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to...
01:20 , Nov 28, 2018 |  BC Extra  |  Company News

Management tracks: Abeona, INKEF, Incyte

Abeona Therapeutics Inc. (NASDAQ:ABEO) terminated Carsten Thiel for personal misconduct towards colleagues, less than eight months after hiring him as CEO. The rare genetic disease company named Head of R&D and CMO João Siffert interim...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
23:20 , Oct 5, 2018 |  BioCentury  |  Finance

Fruitful partnerships

Arix Bioscience plc (LSE:ARIX) leveraged its partnership with Takeda Ventures to co-lead a $58 million series A round for antibody-drug company VelosBio Inc., a sign that the VC’s strategic partnerships are finally bearing fruit. Also...
18:56 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...
06:02 , Aug 10, 2018 |  BC Extra  |  Financial News

Artios raises £65M series B

Artios Pharma Ltd. (Cambridge, U.K.) raised £65 million ($84.3 million) in an oversubscribed, tranched series B round led by new investors Andera Partners and LSP. Fellow new investors Pfizer Ventures and Novartis Venture Fund also...